BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1294437)

  • 21. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
    Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
    J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
    J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
    Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ
    Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival of women with node negative breast cancer in the Auckland region.
    Lethaby AE; Mason BH; Harvey VJ; Holdaway IM
    N Z Med J; 1996 Sep; 109(1029):330-3. PubMed ID: 8862351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
    Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
    Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Demonstration of the effect of estrogen and progesterone receptors on survival in breast cancer without cytostatic and hormonal treatment in a small set of patients].
    Hochmann J
    Klin Onkol; 2010; 23(1):25-33. PubMed ID: 20192071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Follow-up of 551 patients with node-negative breast cancer].
    Eidtmann H; Jonat W; Lange C; Friedrichs K; Maass H
    Geburtshilfe Frauenheilkd; 1992 Aug; 52(8):454-61. PubMed ID: 1397940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical follow-up studies on the prognostic significance of immunohistochemical estrogen receptor determination of breast cancer].
    Beck T; Finger C; Weikel W; Mitze M; Kreienberg R
    Geburtshilfe Frauenheilkd; 1990 Dec; 50(12):935-40. PubMed ID: 2086335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of various factors on survival after recurrent and/or metastatic breast cancer].
    Sevelda P; Kührer I; Zielinski CC; Vavra N; Seifert M; Kubista E; Czerwenka K; Spona J; Salzer H
    Geburtshilfe Frauenheilkd; 1991 May; 51(5):387-92. PubMed ID: 1869009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
    Li HC; Wen XF; Hou YF; Shen KW; Wu J; Lu JS; Shen ZZ; Shao ZM
    Asian J Surg; 2003 Jul; 26(3):163-8. PubMed ID: 12925292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The value of the "vascular invasion" factor for prognosis of breast cancer].
    Kurz C; Obermair A; Nagele F; Czerwenka K; Schemper M; Kubista E; Sevelda P
    Geburtshilfe Frauenheilkd; 1994 May; 54(5):295-9. PubMed ID: 8050691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inflammatory cancer of the breast. Therapy and follow-up].
    Volz J; Volz E; Böhm W; Schneider V
    Geburtshilfe Frauenheilkd; 1992 Apr; 52(4):206-9. PubMed ID: 1607113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
    Pagani O; Gelber S; Simoncini E; Castiglione-Gertsch M; Price KN; Gelber RD; Holmberg SB; Crivellari D; Collins J; Lindtner J; Thürlimann B; Fey MF; Murray E; Forbes JF; Coates AS; Goldhirsch A;
    Breast Cancer Res Treat; 2009 Aug; 116(3):491-500. PubMed ID: 18953651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Thermolabile characteristics of steroid hormone receptors in breast cancer].
    Merkle E; Bähr I; Tulusan AH; Lang N
    Geburtshilfe Frauenheilkd; 1991 Mar; 51(3):182-5. PubMed ID: 2055391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.